- Correction
- Open access
- Published:
Correction: mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company
Journal of Pharmaceutical Policy and Practice volume 16, Article number: 167 (2023)
The Original Article was published on 27 November 2023
Correction: Journal of Pharmaceutical Policy and Practice (2023) 16:158 https://doi.org/10.1186/s40545-023-00652-y
Following publication of the original article [1], it was reported that there were two incorrect references to “liquid nitrogen” in the ‘Supply and logistics’ section. These two instances have been replaced with “dry ice” as follows (correction in bold):
-
This was achieved by shipping the vaccine vials in trays secured within thermal containers cooled with dry ice. This unusual requirement necessitated training of physicians and pharmacists in the safe handling of dry ice and the support of the Swiss military pharmacy for logistics and distribution.
The original article has been updated.
Reference
Killeen T, Kermer V, Troxler Saxer R. mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company. J Pharm Policy Pract. 2023;16:158. https://doi.org/10.1186/s40545-023-00652-y.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Killeen, T., Kermer, V. & Troxler Saxer, R. Correction: mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company. J of Pharm Policy and Pract 16, 167 (2023). https://doi.org/10.1186/s40545-023-00677-3
Published:
DOI: https://doi.org/10.1186/s40545-023-00677-3